- Home
- NRSN vs AQMS Comparison
NRSN vs AQMS Comparison
Compare NRSN & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- AQMS
- Stock Information
- Founded
- NRSN 2017
- AQMS 2014
- Country
- NRSN Israel
- AQMS United States
- Employees
- NRSN N/A
- AQMS N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- AQMS Metal Fabrications
- Sector
- NRSN Health Care
- AQMS Industrials
- Exchange
- NRSN Nasdaq
- AQMS Nasdaq
- Market Cap
- NRSN 17.8M
- AQMS 18.0M
- IPO Year
- NRSN 2021
- AQMS 2015
- Fundamental
- Price
- NRSN $1.14
- AQMS $1.95
- Analyst Decision
- NRSN Hold
- AQMS Strong Buy
- Analyst Count
- NRSN 1
- AQMS 2
- Target Price
- NRSN N/A
- AQMS $30.00
- AVG Volume (30 Days)
- NRSN 360.5K
- AQMS 147.5K
- Earning Date
- NRSN 12-31-2024
- AQMS 11-14-2024
- Dividend Yield
- NRSN N/A
- AQMS N/A
- EPS Growth
- NRSN N/A
- AQMS N/A
- EPS
- NRSN N/A
- AQMS N/A
- Revenue
- NRSN N/A
- AQMS N/A
- Revenue This Year
- NRSN N/A
- AQMS N/A
- Revenue Next Year
- NRSN N/A
- AQMS N/A
- P/E Ratio
- NRSN N/A
- AQMS N/A
- Revenue Growth
- NRSN N/A
- AQMS 525.00
- 52 Week Low
- NRSN $0.51
- AQMS $1.33
- 52 Week High
- NRSN $2.33
- AQMS $17.40
- Technical
- Relative Strength Index (RSI)
- NRSN 56.63
- AQMS 43.66
- Support Level
- NRSN $0.80
- AQMS $1.87
- Resistance Level
- NRSN $1.29
- AQMS $3.00
- Average True Range (ATR)
- NRSN 0.13
- AQMS 0.24
- MACD
- NRSN 0.01
- AQMS -0.01
- Stochastic Oscillator
- NRSN 68.75
- AQMS 14.16
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.